No evidence of clinical benefits of early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: Comment on "Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France".

Lebeaux, David; Revest, Matthieu

Lebeaux, David; Revest, Matthieu.

Lebeaux D; Service de Microbiologie, Unité Mobile d'Infectiologie, AP-HP, Hôpital Européen Georges Pompidou, Université de Paris, France. 20 rue Leblanc, 75015, PARIS, France. Electronic address: david.lebeaux@aphp.fr.
Revest M; Service des Maladies Infectieuses et Réanimation Médicale, CHU Rennes, 2 rue Henri Le Guilloux, 35033, Rennes Cedex, France.

Travel Med Infect Dis ; 36: 101819, 2020.

Article in English | MEDLINE | ID: covidwho-635552

Subject(s)

Betacoronavirus; Coronavirus Infections; Pandemics; Pneumonia, Viral; Azithromycin; COVID-19; Coronavirus Infections/drug therapy; France; Humans; Hydroxychloroquine; Retrospective Studies; SARS-CoV-2; COVID-19 Drug Treatment

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Coronavirus Infections / Pandemics / Betacoronavirus Type of study: Observational study / Prognostic study Limits: Humans Country/Region as subject: Europa Language: English Journal: Travel Med Infect Dis Journal subject: Communicable Diseases Year: 2020 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google